New Zealand's Pharmac reviews funding cetuximab for specific bowel cancer, benefiting 180 patients by Nov 1, 2024.

New Zealand's Pharmaceutical Management Agency (Pharmac) is considering funding cetuximab (Erbitux) for a specific type of bowel cancer, benefiting around 180 patients in the first year. Public consultation is open until August 23rd, with potential funding to take effect from November 1st, 2024. The government provided additional funding to Pharmac in June for new medicines and wider access to existing medications, covering both cancer and non-cancer health conditions.

August 05, 2024
4 Articles